Teva Pharmaceutical Industries (BSP:T1EV34) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 28, 2026)


BSP:T1EV34 Teva Pharmaceutical Industries Ltd BSP:T1EV34
59 GF Score
Price R$85.99
GF Value R$51.72
! 5 Warning Signs
View Full Analysis

What is Teva Pharmaceutical Industries Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Teva Pharmaceutical Industries's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

BSP:T1EV34 vs ZTS, UTHR, VTRS: Margin of Safety % (DCF Earnings Based) Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Teva Pharmaceutical Industries's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Teva Pharmaceutical Industries Margin of Safety % (DCF Earnings Based) vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Teva Pharmaceutical Industries's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Teva Pharmaceutical Industries's Margin of Safety % (DCF Earnings Based) falls into.


BSP:T1EV34
59GF Score
Teva Pharmaceutical Industries Ltd BSP:T1EV34
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Teva Pharmaceutical Industries (BSP:T1EV34) Overvalued in 2026?

Based on GuruFocus' analysis, Teva Pharmaceutical Industries stock appears to be overvalued. The current stock price of R$85.99 is trading 66.3% above its estimated GF Value™ of R$51.72.

Key valuation signals for BSP:T1EV34:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: R$51.72 vs. price of R$85.99 (66.3% above fair value)
  • GF Score™: 59/100 with 5 warning signs

No single metric tells the full story. See the BSP:T1EV34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Teva Pharmaceutical Industries Business Description

Address 124 Dvora HaNevi’a Street, Tel Aviv, ISR, 6944020
Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in two main therapeutic areas: neurology and immunology. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
59GF Score

Get the complete analysis for BSP:T1EV34

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$85.99
Price
R$51.72
GF Value